Unlocking Cell Therapy

Cell-based therapies, particularly those based on chimeric antigen receptor T-cells (CAR-T), have proven to be highly effective for patients with hematological cancers. However, there are numerous obstacles to the use of CAR-T cell therapy for the treatment of solid tumors, including:

​

• Poor immune cell infiltration of and survival within tumors

• Immunosuppressive properties of the tumor microenvironment

• Systemic toxicity issues linked to off-target CAR-T cell reactivity

 

T-SIGn® therapeutics have the potential to be used in combination with CAR-T and other cell therapies to overcome these limitations via expression of target antigens to enhance the activation, survival and efficacy of cell therapies in the solid tumor setting.

 

Akamis Bio has generated promising preclinical data supporting the use of T-SIGn® therapeutics to enhance the efficacy of CAR-T cell therapy in a human tumor xenograft model; key supportive evidence from studies with that model include:

 

• Gene expression profile demonstrating T-SIGn®-mediated tumor microenvironment remodeling

• Enhanced T-cell activation and recruitment of innate immune cells into the tumor

• T-SIGn® transgene payload-driven enhancement of efficacy vs. CAR-T monotherapy

• Clearance of both primary and metastatic tumors